Last reviewed · How we verify
Ra223
Ra223 is an alpha-emitting radiopharmaceutical that targets bone metastases and delivers localized radiation to kill cancer cells.
Ra223 is an alpha-emitting radiopharmaceutical that targets bone metastases and delivers localized radiation to kill cancer cells. Used for Castration-resistant prostate cancer with symptomatic bone metastases.
At a glance
| Generic name | Ra223 |
|---|---|
| Sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Drug class | Alpha-emitting radiopharmaceutical |
| Target | Bone matrix (calcium-mimetic mechanism) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ra223 (radium-223) is an alpha particle-emitting isotope that mimics calcium and preferentially accumulates in bone, particularly at sites of increased osteoblastic activity such as bone metastases. Once localized to metastatic lesions, it delivers high-energy alpha radiation that causes double-strand DNA breaks in cancer cells while minimizing systemic toxicity due to the short range of alpha particles.
Approved indications
- Castration-resistant prostate cancer with symptomatic bone metastases
Common side effects
- Bone marrow suppression (thrombocytopenia, anemia, leukopenia)
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (PHASE1, PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (PHASE2)
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Radium-223 in Biochemically Recurrent Prostate Cancer (PHASE2)
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (PHASE1)
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ra223 CI brief — competitive landscape report
- Ra223 updates RSS · CI watch RSS
- European Organisation for Research and Treatment of Cancer - EORTC portfolio CI